WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting ...
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...
Hosted on MSN
Morgan Stanley initiates coverage of Belite Bio, Inc - depositary receipt (BLTE) with overweight recommendation
Fintel reports that on January 6, 2026, Morgan Stanley initiated coverage of Belite Bio, Inc - Depositary Receipt (NasdaqCM:BLTE) with a Overweight recommendation. Analyst Price Forecast Suggests ...
President Donald Trump was clearly willing to let the stock market melt down after announcing enormous “reciprocal” tariffs on U.S. allies and adversaries alike last week — including levies targeting ...
Morgan Stanley chief equity strategist Michael Wilson says the consensus is significantly underestimating the combined impact of multiple bullish catalysts heading into 2026, with the year’s big ...
Get the best news & discounts for Broadway Shows & beyond.
Copyright © 2025 Insider Inc and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback